273 related articles for article (PubMed ID: 33277605)
1. Association of clozapine-related metabolic disturbances with CYP3A4 expression in patients with schizophrenia.
Menus Á; Kiss Á; Tóth K; Sirok D; Déri M; Fekete F; Csukly G; Monostory K
Sci Rep; 2020 Dec; 10(1):21283. PubMed ID: 33277605
[TBL] [Abstract][Full Text] [Related]
2. Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics.
Tóth K; Csukly G; Sirok D; Belic A; Kiss Á; Háfra E; Déri M; Menus Á; Bitter I; Monostory K
Int J Neuropsychopharmacol; 2017 Jul; 20(7):529-537. PubMed ID: 28340122
[TBL] [Abstract][Full Text] [Related]
3. Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype.
Tóth K; Csukly G; Sirok D; Belic A; Kiss Á; Háfra E; Déri M; Menus Á; Bitter I; Monostory K
Int J Neuropsychopharmacol; 2016 Dec; 19(12):. PubMed ID: 27639091
[TBL] [Abstract][Full Text] [Related]
4. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.
Eiermann B; Engel G; Johansson I; Zanger UM; Bertilsson L
Br J Clin Pharmacol; 1997 Nov; 44(5):439-46. PubMed ID: 9384460
[TBL] [Abstract][Full Text] [Related]
5. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
[TBL] [Abstract][Full Text] [Related]
6. CYP-mediated clozapine interactions: how predictable are they?
Chetty M; Murray M
Curr Drug Metab; 2007 May; 8(4):307-13. PubMed ID: 17504220
[TBL] [Abstract][Full Text] [Related]
7. Effect of lemborexant on pharmacokinetics of clozapine: A potential drug-drug interaction mediated by time-dependent inhibition of CYP3A4.
Watanabe K; Misaka S; Kanno-Nozaki K; Chiyoda T; Suzuki Y; Sato A; Suto T; Kuroda J; Shimomura K; Miura I; Yabe H
Br J Clin Pharmacol; 2024 Jan; 90(1):354-359. PubMed ID: 37596710
[TBL] [Abstract][Full Text] [Related]
8. Genetic Determinants of Clozapine-Induced Metabolic Side Effects.
Vasudev K; Choi YH; Norman R; Kim RB; Schwarz UI
Can J Psychiatry; 2017 Feb; 62(2):138-149. PubMed ID: 27681143
[TBL] [Abstract][Full Text] [Related]
9. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors.
Murray M; Zhang WV; Edwards RJ
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):388-395. PubMed ID: 29155491
[TBL] [Abstract][Full Text] [Related]
10. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients.
Melkersson KI; Scordo MG; Gunes A; Dahl ML
J Clin Psychiatry; 2007 May; 68(5):697-704. PubMed ID: 17503978
[TBL] [Abstract][Full Text] [Related]
11. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
[TBL] [Abstract][Full Text] [Related]
12. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
13. Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia.
Ferrari M; Bolla E; Bortolaso P; Callegari C; Poloni N; Lecchini S; Vender S; Marino F; Cosentino M
Psychiatry Res; 2012 Dec; 200(2-3):1014-7. PubMed ID: 22901441
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.
Lu ML; Lane HY; Lin SK; Chen KP; Chang WH
J Clin Psychiatry; 2004 Jun; 65(6):766-71. PubMed ID: 15291653
[TBL] [Abstract][Full Text] [Related]
15. Semi-physiological Pharmacokinetic Model of Clozapine and Norclozapine in Healthy, Non-smoking Volunteers: The Impact of Race and Genetics.
Albitar O; Harun SN; Sheikh Ghadzi SM
CNS Drugs; 2024 Jul; 38(7):571-581. PubMed ID: 38836990
[TBL] [Abstract][Full Text] [Related]
16. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.
Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia AG; Ventimiglia A; Perucca E
Psychopharmacology (Berl); 2000 Jan; 148(1):83-9. PubMed ID: 10663421
[TBL] [Abstract][Full Text] [Related]
17. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients.
Doude van Troostwijk LJ; Koopmans RP; Vermeulen HD; Guchelaar HJ
Eur J Pharm Sci; 2003 Dec; 20(4-5):451-7. PubMed ID: 14659489
[TBL] [Abstract][Full Text] [Related]
18. Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylclozapine on working memory in schizophrenia.
Islam F; Maciukiewicz M; Freeman N; Huang E; Tiwari A; Mulsant BH; Pollock BG; Remington G; Kennedy JL; Müller DJ; Rajji TK
J Psychopharmacol; 2021 Jan; 35(1):31-39. PubMed ID: 33143542
[TBL] [Abstract][Full Text] [Related]
19. Alcohol intake potentiates clozapine adverse effects associated to CYP1A2*1C in patients with refractory psychosis.
Ortega-Vázquez A; Mayen-Lobo YG; Dávila-Ortiz de Montellano DJ; Tristán-López L; Aviña-Cervantes CL; Ríos C; López-López M; Monroy-Jaramillo N
Drug Dev Res; 2021 Aug; 82(5):685-694. PubMed ID: 33336447
[TBL] [Abstract][Full Text] [Related]
20. [Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine: four case reports].
Papetti F; Morel-Pingault V; Buisse V; Maziere L; Banayan M; Thauby S; Besnard T; Darcourt G; Pringuey D
Encephale; 2007 Oct; 33(5):811-8. PubMed ID: 18357853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
